TTI-314

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTTI-314
Drug Alias NameCD32a-specific monoclonal antibody (Trillium Therapeutics)TTI-314
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-a antagonists
TargetsLow affinity immunoglobulin gamma Fc region receptor II-a
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTrillium Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A